Clene Inc. — Director's Dealing 2021

Jan 4, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Clene Inc. (CLNN)
CIK: 0001822791
Period of Report: 2020-12-30

Reporting Person: Glanzman Robert (N/A)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Incentive Stock Option (right to buy)	$2.3754		Common Stock (290351.00)		Direct

Footnotes

F1: Awarded under the Clene Nanomedicine, Inc. 2014 Stock Plan on August 26, 2019 and currently exercisable. The options will expire 10 years from the date of the grant.